Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Cervical Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 66 articles: HTML format

Single Articles

July 2025
1. BOWDEN SJ, Bodinier B, Paraskevaidi M, Kalliala I, et al
   DNA methylation signatures of cervical pre-invasive and invasive disease: An epigenome-wide association study.
   Int J Cancer. 2025;157:305-316.
   PubMed     Abstract available
   
   
   
2. BJORGE T, Stoer NC, Hverven SK, Nygard M, et al
   Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.
   Int J Cancer. 2025;157:251-259.
   PubMed     Abstract available
   
   
   
3. CHANDRAN A, Mackie A, Sasieni P, Arbyn M, et al
   Technical, legal and ethical framework of cancer audit in cervical screening - Summary of best practices for organised programmes delineated through an expert group consultation.
   Int J Cancer. 2025;157:32-40.
   PubMed     Abstract available
   
   
   June 2025
4. ZHENG Y, Han J, Qu Y, Wang J, et al
   DNA methylation biomarkers for cervical cancer risk prediction in HIV-positive Nigerian women.
   Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35502.
   PubMed     Abstract available
   
   
   April 2025
5. KALJOUW S, Jansen EEL, Schevenhoven VJC, de Kok IMCM, et al
   Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects.
   Int J Cancer. 2025 Apr 28. doi: 10.1002/ijc.35435.
   PubMed     Abstract available
   
   
   
6. WEI Y, Gu L, Zhang Y, Yang Q, et al
   Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.
   Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35450.
   PubMed     Abstract available
   
   
   March 2025
7. ESLAHI M, Pizzato M, Heikkinen S, Martinsen JI, et al
   Socioeconomic position and risk of cervical cancer in the Nordic countries: Results from the Nordic Occupational Cancer Study.
   Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35349.
   PubMed     Abstract available
   
   
   
8. LI Z, Liu P, Yin A, Zhang B, et al
   Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer.
   Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35369.
   PubMed     Abstract available
   
   
   
9. CHEN Q, Yao X, Quan J, Jia X, et al
   The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort study.
   Int J Cancer. 2025;156:1043-1054.
   PubMed     Abstract available
   
   
   February 2025
10. KEBEDE HB, Mekuria S, Asegid N, Forslund O, et al
    High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia: A community-based cohort study.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35335.
    PubMed     Abstract available
    
    
    
11. HARPER DM, Paczos T, Ridder R, Huh WK, et al
    p16/ki-67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35353.
    PubMed     Abstract available
    
    
    January 2025
12. DU L, Sun H, Tang L, Hao S, et al
    Cervical cancer incidence rates considering migration status in mainland China using Bayesian model-Estimation based on 2016 cancer registry data.
    Int J Cancer. 2025 Jan 23. doi: 10.1002/ijc.35346.
    PubMed     Abstract available
    
    
    
13. ARROYO MUHR LS, Wang J, Hassan SS, Yilmaz E, et al
    Nationwide registry-based trial of risk-stratified cervical screening.
    Int J Cancer. 2025;156:379-388.
    PubMed     Abstract available
    
    
    December 2024
14. VERHOEF L, Bleeker MCG, Polman N, Kroon KR, et al
    Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35289.
    PubMed     Abstract available
    
    
    
15. KEN-AMOAH S, Redl E, Domson BKS, Barrett JE, et al
    Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana.
    Int J Cancer. 2024 Dec 10. doi: 10.1002/ijc.35260.
    PubMed     Abstract available
    
    
    November 2024
16. PEDERSEN BT, Sonne SB, Pedersen H, Andreasen EK, et al
    Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.
    Int J Cancer. 2024 Nov 23. doi: 10.1002/ijc.35263.
    PubMed     Abstract available
    
    
    
17. LIU H, Zou M, Shen M, Kamarulzaman A, et al
    HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
    Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242.
    PubMed     Abstract available
    
    
    
18. SCHAAFSMA M, Schuurman TN, Kootstra P, Issa D, et al
    Nationwide cohort study on the risk of high-grade cervical dysplasia and carcinoma after conservative treatment or hysterectomy for adenocarcinoma in situ.
    Int J Cancer. 2024 Nov 4. doi: 10.1002/ijc.35237.
    PubMed     Abstract available
    
    
    
19. LOUVANTO K, Verhoef L, Pimenoff V, Eriksson T, et al
    Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions.
    Int J Cancer. 2024;155:1549-1557.
    PubMed     Abstract available
    
    
    October 2024
20. DESCAMPS P, Bosch Jose FX, Monsonego J, Neisingh O, et al
    Cervical cancer screening: Sharing best practices and addressing common challenges in cervical cancer screening programs.
    Int J Cancer. 2024 Oct 26. doi: 10.1002/ijc.35220.
    PubMed    
    
    
    
21. LEHTINEN M, Elfstrom M, Vanska S, Dillner J, et al
    Elimination of cervical cancer by refined vaccination and screening.
    Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35228.
    PubMed    
    
    
    
22. KOKEMULLER L, Ramachandran D, Schurmann P, Geffers R, et al
    Germline variants of homology-directed repair or mismatch repair genes in cervical cancer.
    Int J Cancer. 2024 Oct 23. doi: 10.1002/ijc.35221.
    PubMed     Abstract available
    
    
    
23. MISHRA GA, Pimple SA, Anand KV, Kulkarni VY, et al
    Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35222.
    PubMed     Abstract available
    
    
    
24. CUI M, Song L, Mao R, Lyu Y, et al
    Exposure to polycyclic aromatic hydrocarbons promotes the progression of low-grade cervical intraepithelial neoplasia: A population-based cohort study in China.
    Int J Cancer. 2024;155:1162-1171.
    PubMed     Abstract available
    
    
    September 2024
25. CHEN J, Shi J, Cao Y, Li C, et al
    A new treatment approach of toripalimab in combination with concurrent platinum-based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial.
    Int J Cancer. 2024 Sep 28. doi: 10.1002/ijc.35206.
    PubMed     Abstract available
    
    
    
26. DEBEAUDRAP P, Kabore FN, Setha L, Tegbe J, et al
    Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35190.
    PubMed     Abstract available
    
    
    
27. OSTRBENK VALENCAK A, Kroon KR, Fabjan D, Mlakar J, et al
    Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
    Int J Cancer. 2024 Sep 24. doi: 10.1002/ijc.35200.
    PubMed     Abstract available
    
    
    
28. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Int J Cancer. 2024;155:905-915.
    PubMed     Abstract available
    
    
    August 2024
29. SCHAAFSMA M, van den Helder R, Mom CH, Steenbergen RDM, et al
    Recurrent cervical cancer detection using DNA methylation markers in self-collected samples from home.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35143.
    PubMed     Abstract available
    
    
    July 2024
30. LYNGE E, Bennekou Schroll J, Andersen B, Balasubramaniam K, et al
    Cervical cancer incidence in Denmark: Disentangling determinants of time trend.
    Int J Cancer. 2024 Jul 14. doi: 10.1002/ijc.35081.
    PubMed     Abstract available
    
    
    
31. MORO F, Ciancia M, Zace D, Vagni M, et al
    Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
    PubMed     Abstract available
    
    
    
32. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
    Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
    Int J Cancer. 2024;155:81-92.
    PubMed     Abstract available
    
    
    May 2024
33. LOBIN C, Orang'o EO, Were E, Muthoka K, et al
    Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya.
    Int J Cancer. 2024 May 27. doi: 10.1002/ijc.35036.
    PubMed     Abstract available
    
    
    
34. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
    Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
    Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
    PubMed     Abstract available
    
    
    April 2024
35. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available
    
    
    
36. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    PubMed     Abstract available
    
    
    March 2024
37. PORTNOY A, Pedersen K, Sy S, Trope A, et al
    Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Int J Cancer. 2024;154:1073-1081.
    PubMed     Abstract available
    
    
    
38. LI N, Yi H, Sun W, Sundquist J, et al
    Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34911.
    PubMed     Abstract available
    
    
    
39. STERPETTI AV, Gabriele R, Iannone I, Sapienza P, et al
    Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34907.
    PubMed    
    
    
    
40. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    PubMed     Abstract available
    
    
    February 2024
41. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available
    
    
    
42. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    PubMed     Abstract available
    
    
    January 2024
43. AMBOREE TL, Damgacioglu H, Sonawane K, Adsul P, et al
    Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019.
    Int J Cancer. 2024 Jan 25. doi: 10.1002/ijc.34860.
    PubMed     Abstract available
    
    
    
44. LEHTINEN M, Bruni L, Elfstrom M, Gray P, et al
    Scientific approaches toward improving cervical cancer elimination strategies.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34839.
    PubMed     Abstract available
    
    
    
45. EL-ZEIN M, Cheishvili D, Szyf M, Franco EL, et al
    Validation of novel DNA methylation markers in cervical precancer and cancer.
    Int J Cancer. 2024;154:104-113.
    PubMed     Abstract available
    
    
    December 2023
46. 
    Harald zur Hausen 1936-2023.
    Int J Cancer. 2023;153:1937-1939.
    PubMed    
    
    
    
47. DICK S, Heideman DAM, Mom CH, Meijer CJLM, et al
    Methylation testing for the detection of recurrent cervical intraepithelial neoplasia.
    Int J Cancer. 2023;153:2011-2018.
    PubMed     Abstract available
    
    
    November 2023
48. TULSIDAS S, Fontes F, Monteiro K, Mussa M, et al
    Cervical cancer in Mozambique: Clinical characteristics, treatment and survival of incident cases admitted to the Oncology Service of Maputo Central Hospital in 2016-2018.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34779.
    PubMed     Abstract available
    
    
    
49. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    PubMed     Abstract available
    
    
    October 2023
50. 
    Correction to "Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34775.
    PubMed    
    
    
    
51. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    PubMed     Abstract available
    
    
    September 2023
52. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    PubMed     Abstract available
    
    
    
53. MUNGO C, Osongo CO, Ambaka J, Omoto J, et al
    Efficacy of thermal ablation for treatment of biopsy-confirmed high-grade cervical precancer among women living with HIV in Kenya.
    Int J Cancer. 2023 Sep 15. doi: 10.1002/ijc.34737.
    PubMed     Abstract available
    
    
    
54. WANG J, Edvardsson H, Strander B, Andrae B, et al
    Long-term follow-up of cervical cancer incidence after normal cytological findings.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34723.
    PubMed     Abstract available
    
    
    
55. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    
56. FERNANDEZ VILLALOBOS NV, Ruffieux Y, Haas AD, Chinogurei C, et al
    Cervical precancer and cancer incidence among insured women with and without HIV in South Africa.
    Int J Cancer. 2023 Sep 2. doi: 10.1002/ijc.34707.
    PubMed     Abstract available
    
    
    August 2023
57. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    PubMed     Abstract available
    
    
    July 2023
58. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    PubMed     Abstract available
    
    
    June 2023
59. QI L, Wang M, Jia Y, Wang Y, et al
    Impact of the COVID-19 pandemic on the hospital attendance of patients with primary cervical cancer in Heilongjiang, China.
    Int J Cancer. 2023 Jun 1. doi: 10.1002/ijc.34617.
    PubMed     Abstract available
    
    
    May 2023
60. PESOLA F, Rebolj M, Sasieni P
    Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
    Int J Cancer. 2023;152:2061-2068.
    PubMed     Abstract available
    
    
    April 2023
61. TISLER A, Nygard M, Kivite-Urtane A, Berza N, et al
    Comment on "The European response to the WHO call to eliminate cervical cancer as a public health problem".
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34540.
    PubMed    
    
    
    March 2023
62. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    PubMed     Abstract available
    
    
    
63. WEVER BMM, van den Helder R, van Splunter AP, van Gent MDJM, et al
    DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples, and cervical scrapes.
    Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34504.
    PubMed     Abstract available
    
    
    
64. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    PubMed     Abstract available
    
    
    February 2023
65. HERZOG C, Vavourakis CD, Barrett JE, Karbon G, et al
    HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2023 Feb 21. doi: 10.1002/ijc.34477.
    PubMed     Abstract available
    
    
    December 2022
66. BARRETT JE, Jones A, Evans I, Herzog C, et al
    The WID-EC test for the detection and risk prediction of endometrial cancer.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34406.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.